Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer  • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test  • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial  • Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancerPresenters:Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, France  Ignace Vergote, MD, PhDProfessor Em. of Department of Obstetrics and Gynecologic OncologyUniversity Hospitals LeuvenLeuven, BelgiumContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.